Home › Compound Library › Ayahuasca (DMT + Harmaline)

Ayahuasca (DMT + Harmaline)

Psychedelicoral · inferred

Traditional Amazonian brew combining DMT-containing plants (Psychotria viridis) with beta-carboline MAO inhibitors (Banisteriopsis caapi, containing harmine, harmaline, and tetrahydroharmine). The harmalas inhibit MAO-A, preventing first-pass DMT destruction and extending its half-life from minutes to ~4 hours orally. Effects last 4-6 hours. THH (t1/2 ~6h) also contributes mild serotonergic and SSRI-like effects.

Projected serum levels — 100 mL (≈ 30 mg), as needed (shown daily)

Ayahuasca (DMT + Harmaline)
Ayahuasca (DMT + Harmaline) modeled serum levels, 100 mL (≈ 30 mg) as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 5 days. 0 2.5 5 7.5 10 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 5
Ayahuasca (DMT + Harmaline) modeled serum levels with a loading dose of 295 mL, then 100 mL (≈ 30 mg) as needed (shown daily) The first dose is larger so levels approach steady state faster. 0 2.5 5 7.5 10 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 100 mL (≈ 30 mg) as needed (shown daily) (oral).

Loading schedule: 295 mL on day 1, then 100 mL (≈ 30 mg) as needed (shown daily) — reaching therapeutic levels sooner.

Modeled steady state after ~5 days: peak ≈ 5.0 mg, trough ≈ 3.5 mg body load. Population-based estimate over 15 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Psychedelic
Route modeled
Oral
Model confidence
inferred
Half-life
41 h
Common dose
100 mL (≈ 30 mg)
Reference dose range
50–200 mL (single dose)
Suggested cadence
as needed (shown daily)

Documented interactions

  • danger
    1P-LSD (1-Propionyl-LSD) + Ayahuasca (DMT + Harmaline) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and Ayahuasca (DMT + Harmaline) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    25I-NBOMe + Ayahuasca (DMT + Harmaline) Serotonin risk

    25I-NBOMe and Ayahuasca (DMT + Harmaline) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    2C-I (2,5-Dimethoxy-4-iodophenethylamine) + Ayahuasca (DMT + Harmaline) Serotonin risk

    2C-I (2,5-Dimethoxy-4-iodophenethylamine) and Ayahuasca (DMT + Harmaline) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental…

  • danger
    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) + Ayahuasca (DMT + Harmaline) Stacked effects

    2C-B (4-Bromo-2,5-dimethoxyphenethylamine) and Ayahuasca (DMT + Harmaline) both push the serotonin 5HT1A, serotonin 5HT2A, and serotonin 5HT2C in the same direction.

  • danger
    3-MeO-PCP (3-Methoxyphencyclidine) + Ayahuasca (DMT + Harmaline) Serotonin risk

    3-MeO-PCP (3-Methoxyphencyclidine) and Ayahuasca (DMT + Harmaline) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

  • danger
    4-AcO-DMT (Psilacetin) + Ayahuasca (DMT + Harmaline) Stacked effects

    4-AcO-DMT (Psilacetin) and Ayahuasca (DMT + Harmaline) both push the serotonin 5HT1A, serotonin 5HT2A, and serotonin 5HT2C in the same direction.

Serum checks 187 modeled interaction pairings for ayahuasca (dmt + harmaline) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Pharmacokinetics and pharmacodynamics of an innovative psychedelic N,N-dimethyltryptamine/harmine formulation in healthy participants: a randomized controlled trial van der Heijden R et al. · International Journal of Neuropsychopharmacology, 2025 DOI

    RCT of standardized DMT/harmine formulation characterizing bidirectional PK interaction: harmine extends DMT half-life via MAO-A inhibition while DMT alters harmine pharmacokinetics.

  2. Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact Dinis-Oliveira RJ · Pharmaceuticals, 2020 DOI

    Comprehensive review of ayahuasca alkaloid toxicokinetics including DMT, harmine, harmaline, and THH pharmacokinetics, metabolism pathways, and clinical/forensic implications.

  3. Pharmacokinetics of Hoasca alkaloids in healthy humans Callaway JC et al. · Journal of Ethnopharmacology, 1999 DOI

    Landmark study of ayahuasca alkaloid pharmacokinetics in 15 volunteers showing DMT Tmax ~107 min, harmine rapid absorption and elimination, and THH as the longest-lasting component (~6h half-life).

3 published studies referenced in the app, each with a plain-language summary.